Fortis Therapeutics Overview
- Year Founded
-
2010
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
Fortis Therapeutics General Information
Description
Developer of an immune-oncology drug designed to focus on the treatment of multiple myeloma and late-stage prostate cancer. The company prepares an antibody-drug conjugate for both adenocarcinoma and neuroendocrine cancer, enabling doctors to treat late-stage cancers effectively.
Contact Information
Website
www.fortistx.comCorporate Office
- 11099 North Torrey Pines Road
- Suite 290
- La Jolla, CA 92037
- United States
Corporate Office
- 11099 North Torrey Pines Road
- Suite 290
- La Jolla, CA 92037
- United States
Fortis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | 01-Jul-2026 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC (Series A) | 29-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 1. Later Stage VC (Series A) | 28-Sep-2016 | $18M | $18M | Completed | Startup |
Fortis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Fortis Therapeutics Patents
Fortis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022205348-A1 | Combination therapy with for46 for cancer | Pending | 07-Jan-2021 | ||
| AU-2022205348-A9 | Combination therapy with for46 for cancer | Pending | 07-Jan-2021 | ||
| CA-3204579-A1 | Combination therapy with for46 for cancer | Pending | 07-Jan-2021 | ||
| EP-4274661-A1 | Combination therapy with for46 for cancer | Pending | 07-Jan-2021 | ||
| EP-4274661-A4 | Combination therapy with for46 for cancer | Pending | 07-Jan-2021 | A61K47/6849 |
Fortis Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avalon Bioventures | Venture Capital | Minority | ||
| Fulcrum 2020 | Other | Minority | ||
| Myeloma Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| Prostate Cancer Foundation | Not-For-Profit Venture Capital | Minority | ||
| UCSF Innovation Ventures | Venture Capital | Minority |
Fortis Therapeutics FAQs
-
When was Fortis Therapeutics founded?
Fortis Therapeutics was founded in 2010.
-
Where is Fortis Therapeutics headquartered?
Fortis Therapeutics is headquartered in La Jolla, CA.
-
What industry is Fortis Therapeutics in?
Fortis Therapeutics’s primary industry is Drug Discovery.
-
Is Fortis Therapeutics a private or public company?
Fortis Therapeutics is a Private company.
-
What is Fortis Therapeutics’s current revenue?
The current revenue for Fortis Therapeutics is .
-
How much funding has Fortis Therapeutics raised over time?
Fortis Therapeutics has raised $58M.
-
Who are Fortis Therapeutics’s investors?
Avalon Bioventures, Fulcrum 2020, Myeloma Investment Fund, Prostate Cancer Foundation, and UCSF Innovation Ventures are 5 of 8 investors who have invested in Fortis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process